Cleared Traditional

K102607 - FIDISTM CONNECTIVE 10, FIDISTM ANALYZER, CARIS

K102607 is an FDA 510(k) clearance for FIDISTM CONNECTIVE 10, manufactured by Biomedical Diagnostics (Bmd) SA. The device is a Class 2 Immunology device with product code LLL cleared through the Traditional 510(k) pathway after a 84-day FDA review.

K102607 · Biomedical Diagnostics (Bmd) SA · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2010
Decision
84d
Days
Class 2
Risk

K102607 is an FDA 510(k) clearance for the FIDISTM CONNECTIVE 10, FIDISTM ANALYZER, CARIS. Classified as Extractable Antinuclear Antibody, Antigen And Control (product code LLL), Class II - Special Controls.

Submitted by Biomedical Diagnostics (Bmd) SA (Marne La Vallee Cedex 2, FR). The FDA issued a Cleared decision on December 3, 2010 after a review of 84 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Biomedical Diagnostics (Bmd) SA devices

FDA 510(k) Submission Details - K102607

510(k) Number K102607 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 10, 2010
Decision Date December 03, 2010
Days to Decision 84 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
21d faster than avg
Panel avg: 105d · This submission: 84d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LLL Device Classification - Class 2, Special Controls

Product Code LLL Extractable Antinuclear Antibody, Antigen And Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LLL Extractable Antinuclear Antibody, Antigen And Control

All 138
Devices cleared under the same product code (LLL) and FDA review panel - the closest regulatory comparables to K102607.
QUANTA FLASH SS-B, QUANTA FLASH SS-B CALIBRATORS, AND QUANTA FLASH SS-B CONTROLS
K141210 · Inova Diagnostics, Inc. · Jan 2015
QUANTA FLASH ENA7
K122923 · Inova Diagnostics, Inc. · May 2013
IMMULISA SCI-70 ANTIBODY ELISA
K113143 · Immco Diagnostics, Inc. · Dec 2011
ELIA SYMPHONY IMMUNOASSAY, ANA CONTROL, MODEL 14-55508-01,83-1004-01
K072149 · Phadia US, Inc. · Jan 2008
QUANTA PLEX SLE PROFILE 8
K040160 · Inova Diagnostics, Inc. · Mar 2004
QUANTA PLEX ENA PROFILE 6
K031450 · Inova Diagnostics, Inc. · Jun 2003